Abstract: This disclosure relates to methods of treating, e.g., complex regional pain syndrome (CRPS) using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).

Abstract: Disclosed herein are methods of treating, e.g., Raynaud's syndrome and/or scleroderma in a subject in need thereof, using cilnidipine optionally in combination with tadalafil.

Abstract: Disclosed herein are methods of treating diseases and disorders using (i) dual N-type and L-type calcium channel blockers selective for the N-type calcium channel and/or (ii) Nav 1.7 sodium channel blockers, including cilnidipine.

Abstract: Disclosed herein are methods of treating Raynaud's syndrome (e.g., secondary Raynaud's syndrome) in a subject in need thereof, using a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel and/or a phosphodiesterase type 5 inhibitor.

Abstract: This disclosure relates to methods of treating, e.g., pain using cilnidipine and p-glycoprotein inhibitors (e.g., ritonavir).

Abstract: Disclosed herein are methods of treating, e.g., scleroderma in a subject in need thereof, using a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel.

Abstract: This disclosure relates to methods of treating, e.g., eye pain and eye disorders, using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).

Abstract: Disclosed herein are methods of treating diseases and disorders using (i) dual N-type and L-type calcium channel blockers selective for the N-type calcium channel and/or (ii) Nav 1.7 sodium channel blockers, including cilnidipine.

Abstract: Disclosed herein are methods of treating Raynaud's syndrome (e.g., secondary Raynaud's syndrome) in a subject in need thereof, using a dual N-type and L-type calcium channel blocker selective for the N-type calcium channel and/or a phosphodiesterase type 5 inhibitor.

Abstract: Methods, kits and compositions are disclosed that include an isolated kallikrein inhibitor for the treatment of mucositis.

Abstract: Methods, kits and compositions are disclosed that include an isolated kallikrein inhibitor for the treatment of mucositis.

Abstract: The invention features a method of inhibiting the progression of intima-media thickening, or reducing the intima-media thickness (IMT) in arteries in a patient in need thereof by administering to the patient a rifamycin in an amount effective to inhibit the progression of intima-media thickening, or reduce the IMT. The invention also features a method for treating or preventing cerebral vascular disease in a patient in need thereof by administering to the patient a rifamycin in an amount effective to treat the cerebral vascular disease in the patient.

Abstract: The invention relates to the treatment of peripherial arterial occlusive disease.

Abstract: A client care method, system, and computer program product which provides a package of accommodation, concierge, and/or clinical services to clients outside of a medical facility. The clients may be bundles to share service providers at the same geographic location.